Abstract 5066
Background
Receiving a diagnosis of cancer may be associated with increased psychosocial distress. Without objective assessments, healthcare professionals tend to underestimate psychological distress, and fail in the recognition, triage and referral of distressed patients. The specific aims of this study are to identify the level and the nature of the distress.
Methods
A descriptive prospective design has been used to analyze the data of distress thermometer (DT) in initial visits in the cancer unit. Data collection was conducted by nurses over a six month period. The variables studied were: age, sex, type of tumor, intensity and causes of distress.
Results
39 patients answered the DT screening tool. On average, the participants were 58.1 years old and 64% of them were female. The most frequent diagnoses reported were breast cancer (38%) and colon cancer (26%). 41 % rated over the cut point of DT (>4) and were referred to psycho-oncology attention. Only the 48 % attended to the psychologist after referral despite the most frequent causes of distress were physical problems (85%) and emotional problems (70%). Finally, there were a statistically significant association between intensity of distress and emotional problems (r = 0,648; p < 0, 001) but not with other problematic areas (physical, family, spiritual or practical).
Conclusions
Psychosocial distress in recently diagnosed cancer patients seems to be related with emotional problems. It is important to evaluate and manage emotional distress in these patients to improve their quality of life and refer patients to the psychologist when it is necessary.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
E Bailles.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5056 - Phase 2 study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
5710 - Avelumab for advanced Merkel cell carcinoma in the Netherlands; a nationwide survey
Presenter: Sonja Levy
Session: Poster Display session 3
Resources:
Abstract
3152 - Health-related quality of life in patients with metastatic Merkel cell carcinoma receiving second-line or later avelumab treatment: 36-month follow-up data
Presenter: Sandra D'Angelo
Session: Poster Display session 3
Resources:
Abstract
5715 - A Phase 2, Randomized Study of Nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and Stereotactic Body Radiation Therapy (SBRT) for Metastatic Merkel Cell Carcinoma (MCC, NCT03071406) – a preliminary report.
Presenter: Sungjune Kim
Session: Poster Display session 3
Resources:
Abstract
2854 - Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma
Presenter: Kalijn Bol
Session: Poster Display session 3
Resources:
Abstract
2928 - Immune checkpoint inhibitors in a cohort of 206 metastatic uveal melanomas patients
Presenter: Mathilde Saint-Ghislain
Session: Poster Display session 3
Resources:
Abstract
1235 - Incidence and survival of Uveal Melanoma occurring as single cancer versus its occurrence as a first or second primary neoplasm
Presenter: Ahmad Alfaar
Session: Poster Display session 3
Resources:
Abstract
3615 - Validation of a Clinicopathological and Gene Expression Profile (CP-GEP) Model for Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma
Presenter: Evalyn Mulder
Session: Poster Display session 3
Resources:
Abstract
1793 - External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC) using the Surveillance, Epidemiology and End Results (SEER) Program
Presenter: Angelina Tjokrowidjaja
Session: Poster Display session 3
Resources:
Abstract
4278 - Clinical factors and overall survival (OS) associated with patterns of metastases (mets) in melanoma patients (pts).
Presenter: Ines Pires da Silva
Session: Poster Display session 3
Resources:
Abstract